The World Health Organization (WHO) has issued a global warning concerning the rise of counterfeit versions of Ozempic, a medication primarily intended for type 2 diabetes management but increasingly used off-label for weight loss. Known colloquially as the “skinny jab,” Ozempic’s popularity has surged, leading to its misuse and subsequent shortages for diabetic patients.
Counterfeit Ozempic has become a significant concern, with the WHO tracking increasing instances of these fake drugs worldwide since 2022. Illegal batches have been intercepted in the UK, US, and Brazil, where they were found to be circulated through dubious online platforms and social media channels rather than legitimate pharmaceutical sources.
The composition of these falsified medications is particularly alarming. Some batches have been discovered without any semaglutide—the active ingredient in Ozempic—while others contain different substances, such as insulin, which can lead to unpredictable and potentially harmful health effects.
The WHO advises the public, healthcare professionals, and regulatory authorities to remain vigilant and procure the drug solely through reputable medical channels. This precaution is crucial not only to ensure the effectiveness of the treatment but also to avoid the serious risks associated with unverified products.
Meanwhile, in response to the ongoing demand for weight loss solutions, a higher dosage variant of Ozempic known as Wegovy has been developed and is now available through specialist clinics. This offers a safer and regulated option for those seeking medical assistance in weight management.